Valuation : Revance Therapeutics, Inc.

Market Cap 319M 275M 260M 236M 442M 30.47B 445M 3.09B 1.19B 15.5B 1.2B 1.17B 48.98B P/E 2022
-3.77x
P/E 2023 -2.3x
Enterprise Value 543M 468M 443M 402M 754M 51.92B 758M 5.27B 2.02B 26.41B 2.04B 2B 83.46B EV / Sales 2022
12x
EV / Sales 2023 4.26x
Free-Float
91.93%
Yield 2022 *
-
Yield 2023 -
3 years 2.3
Extreme 2.3
17.59
5 years 2.3
Extreme 2.3
37.98
10 years 2.3
Extreme 2.3
37.98
Manager TitleAgeSince
Chief Executive Officer 55 2025-09-30
General Counsel - 2025-02-03
Director TitleAgeSince
Chairman - 2025-09-30
Date Insider Type Main position Quantity % Market Cap. Importance
2/4/25 Tender

Chairman

51,506 0.0493%
2/4/25 Tender

Director

31,561 0.0302%
2/4/25 Tender

General Counsel

180,044 0.1725%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%-.--%-.--%-77.34% 383M
-1.48%-5.59%+39.55%-6.16% 78.04B
+5.38%-1.09%+512.38%+36.80% 57.48B
-1.42%-4.24%-19.59%-38.20% 57.4B
-0.56%-2.21%-11.34%+27.29% 48.81B
+1.93%-2.37%-0.87%+149.45% 45.5B
+0.80%-1.67%+49.90%-15.98% 32.08B
-1.47%-4.17%+46.17%+89.12% 24.62B
-0.85%-8.64%-4.39%+161.31% 20.77B
-0.09%-3.61%+62.49%+98.37% 15.75B
Average +0.25%-3.49%+67.43%+42.47% 38.08B
Weighted average by Cap. +0.38%-3.71%+90.46%+37.09%

Financials

2022 2023
Net sales 133M 114M 108M 98.03M 184M 12.66B 185M 1.28B 494M 6.44B 498M 487M 20.36B 234M 202M 191M 173M 325M 22.36B 326M 2.27B 872M 11.38B 879M 860M 35.94B
Net income -356M -307M -291M -264M -494M -34.05B -497M -3.45B -1.33B -17.32B -1.34B -1.31B -54.74B -324M -279M -264M -240M -449M -30.95B -452M -3.14B -1.21B -15.75B -1.22B -1.19B -49.76B
Net Debt 77.76M 67M 63.44M 57.5M 108M 7.43B 108M 753M 290M 3.78B 292M 286M 11.94B 225M 193M 183M 166M 311M 21.45B 313M 2.18B 837M 10.91B 843M 825M 34.48B
Logo Revance Therapeutics, Inc.
Revance Therapeutics Inc is a United States-based pharmaceutical preparation manufacturing company. The Company operates as a biotechnology company that develops, manufactures, and markets aesthetic and therapeutic products. It offers products and services, such as DAXXIFY (DaxibotulinumtoxinA-lanm) and resilient hyaluronic acid (RHA) collection, includes aesthetics and therapeutics.
Employees
597
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. RVNC Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!